Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 9Lung Neoplasms 9Oropharyngeal Neoplasms 7Mouth Neoplasms 6Laryngeal Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Stomach Neoplasms 4Hypopharyngeal Neoplasms 4Breast Neoplasms 4Adenocarcinoma of Lung 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Paranasal Sinus Neoplasms 2Ovarian Neoplasms 2Medulloblastoma 2Lymphoid Interstitial Pneumonia 2Liver Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Anus Neoplasms 2Urethral Neoplasms 1

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1berzosertib 1aldesleukin 1Platinum 1Immunoglobulin G 1Gemcitabine 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Bladder Urothelial Carcinoma × Platinum × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡